^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Vβ10 TCR stimulant

    Related drugs:
    3ms
    Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models. (PubMed, J Immunother Cancer)
    These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recurrent or metastatic HPV- HNSCC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    cisplatin • invikafusp alfa (STAR0602)
    10ms
    START-002: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Marengo Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Trodelvy (sacituzumab govitecan-hziy) • invikafusp alfa (STAR0602)
    12ms
    START-002: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Marengo Therapeutics, Inc.
    New P1/2 trial
    |
    Trodelvy (sacituzumab govitecan-hziy) • invikafusp alfa (STAR0602)